Answers are grounded in this paper and cite their sources.
Delays in TB care, in any form, including patient delay, diagnosis delay and treatment delay, are detrimental to both patients and the community. These delays can further sustain transmission in the community. Given this background, this study aims to quantify delays in TB care across high-burden countries worldwide and assess the impact of the COVID-19 pandemic on these delays. The data extraction was conducted using the PUBMED, Scopus, Embase, and Web of Science databases. Using accepted statistical techniques, studies reporting medians with interquartile ranges (IQRs) were converted to means and SDs, and the pooled mean delays for all three types (patient, diagnosis and treatment delays) were estimated with a 95% confidence interval using the random-effects model with the DerSimonian–Laird estimator. Heterogeneity, publication bias and the sensitivity of the included studies were presented graphically and statistically. Our systematic search targeted the top eight high-burden countries; however, we could not retrieve any studies from the Democratic Republic of Congo through databases or hand search. The final analysis included 79 studies from the top seven countries that collectively bear 63% of the global TB burden. The total sample across the studies was 64,77,766, with a median and IQR of 450 (212–2054). The estimated pooled mean patient delay was 24.65 (95% CI: 21.19–28.10) days, diagnosis delay was 18.78 (95% CI: 16.23–21.33) days, and treatment delay was 8.96 (95% CI: 7.64–10.28) days. Across the countries, India had both the highest mean patient delay of 129.33 (95% CI: 26.32-232.35) days and treatment delay of 149.67 (95% CI: 74.54-224.79) days, and Bangladesh had the highest mean diagnosis delay of 93.50 (95% CI: 55.13-131.87) days. Considerable heterogeneity was observed across three delay types, with I2 of 95.35%, 95.36%, and 97.78%, and major asymmetry was observed in the funnel plot and LFK index of 3.95, 8.33, and 7.31, respectively, for patient, diagnosis, and treatment delays, warranting cautious interpretation of the results. The marginal analysis showed a heterogeneous trend with respect to the impact of COVID-19 on delay types across the high-burden countries. Although there is varied documented evidence on the timeframe regarding delays in TB care, a total delay of 30 days is considered unacceptable, with two weeks on either side: patient and health system delay. Given this, the estimated delay through this review falls beyond the acceptable range, which the programme managers and policy actors should take cognisance of to improve timely TB care.
No takes yet. Share an insight, caveat, or question.
Samal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: